Plain-English translation of NCT06486051 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called WZTL-002, which uses your own immune cells to fight large B-cell lymphoma that has come back or stopped responding to previous therapies. The medication is a type of CAR T-cell therapy—your blood cells are collected, modified in a laboratory to better recognize and attack lymphoma cells, and then returned to your body. This is a phase 2 study, meaning researchers are evaluating how well and how safely the treatment works in patients like you.
Many patients with large B-cell lymphoma that returns after initial treatment or doesn't respond to treatment have limited options and face a poor outlook. This medication is designed to harness the power of your own immune system in a new way, and this trial aims to see if it can offer hope to patients who have exhausted other treatments.
You likely qualify if…
You likely don't qualify if…
First, doctors will collect your blood cells through a procedure called leukapheresis (similar to donating blood plasma). Your cells will then be sent to a laboratory for about 3–4 weeks to be modified. Once ready, you'll receive two weeks of mild chemotherapy to prepare your body, followed by a single infusion of the treated cells. You'll spend about two weeks in close monitoring for any side effects, then return for scans and blood tests at 1 month, 3 months, 6 months, 12 months, and 24 months to see how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
New Zealand